{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":20,"n_cols":5,"rows_kept":20,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[12,2,12,3],[13,2,13,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNISA996211169103316"]
[null,null,"Titolo",null,"Evaluating pharmaceuticals for health policy and reimbursement [[electronic resource] /] / edited by Nick Freemantle and Suzanne Hill"]
[null,null,"Pubbl/distr/stampa",null,"Malden, Mass., : BMJ Books/Blackwell Pub., 2004"]
[null,null,"ISBN",null,"1-280-19728-5"]
[{"$nulls":4},"9786610197286"]
[{"$nulls":4},"0-470-79102-0"]
[{"$nulls":4},"0-470-99471-1"]
[{"$nulls":4},"1-4051-4097-6"]
[null,null,"Descrizione fisica",null,"1 online resource (280 p.)"]
[null,null,"Disciplina",null,"362.17/82"]
[{"$nulls":4},"362.1782"]
[null,null,"Soggetti",null,"Pharmaceutical policy"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Development of marketing authorisation procedures for pharmaceuticals / Alar Irs, Truus Janse de Hoog, Lembit Rägo -- Interpreting clinical evidence / Nick Freemantle ... [et al.] -- International pharmaceutical policy: health creation or wealth creation? / Karen Bloor, Alan Maynard -- Development of fourth hurdle policies around the world / Rod S. Taylor ... [et al.] -- Economic modelling in drug reimbursement / Glenn Salkeld, Nick Freemantle, Bernie O'Brien -- Priority setting in health care: matching decision criteria with policy objectives / Gina Brinsmead, Alan Williams -- Tensions in licensing and reimbursement decisions: the case of riluzole for amyotrophic lateral sclerosis / Stirling Bryan ... [et al.] --"]
[{"$nulls":4},"Relationships between stakeholders: managing the war of words / Suzanne Hill, Kees de Joncheere -- Medicine and the media: good information or misleading hype? / Ray Moynihan, Lisa M. Schwartz, Steven Woloshin -- How to promote quality use of cost-effective medicines / Hans Hogerzeil, Kathleen Holloway -- Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable / Andrew Mitchell -- Pricing of pharmaceuticals / David Newby, Andrew Creese, Alan Stevens -- Evaluating pharmaceuticals for health policy in low and middle income country settings / Andrew Creese ... [et al.]."]
[null,null,null,"Sommario/riassunto","\"The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable\"   So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders."]